

DESCRIPTION

Source	Human embryonic kidney cell, HEK293-derived sars-cov-2 Spike RBD protein	
	<p>SARS-CoV-2 EG.5.1 Spike RBD (Arg319-Phe541) (Gly339His, Arg346Thr, Leu368Ile, Ser371Phe, Ser373Pro, Ser375Phe, Thr376Ala, Asp405Asn, Arg408Ser, Lys417Asn, Asn440Lys, Val445Pro, Gly446Ser, Phe456Leu, Asn460Lys, Ser477Asn, Thr478Lys, Glu484Ala, Phe486Pro, Phe490Ser, Gln498Arg, Asn501Tyr, Tyr505His) Accession # YP_009724390.1</p>	<p>6-His tag</p>
	N-terminus	C-terminus

N-terminal Sequence Analysis	Arg319
Predicted Molecular Mass	26 kDa

SPECIFICATIONS

SDS-PAGE	34-38 kDa, under reducing conditions.
Activity	Measured by its binding ability in a functional ELISA with Recombinant Human ACE-2 Fc Chimera (Catalog # 10544-ZN).
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 500 µg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	<p>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</p> <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

DATA

<p>Binding Activity</p> <p>Recombinant SARS-CoV-2 EG.5.1 Spike RBD His-tag Protein Binding Activity. Recombinant SARS-CoV-2 EG.5.1 Spike RBD His-tag Protein (Catalog # 11442-CV) binds Recombinant Human ACE-2 Fc Chimera (Catalog # 10544-ZN) in a functional ELISA.</p>	<p>SDS-PAGE</p> <p>Recombinant SARS-CoV-2 EG.5.1 Spike RBD His-tag Protein SDS-PAGE. 2 µg/lane of Recombinant SARS-CoV-2 EG.5.1 Spike RBD His-tag Protein (Catalog # 11442-CV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 34-38 kDa, under reducing conditions.</p>
--	--

BACKGROUND

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that also include MERS-CoV and SARS-CoV-1. Coronaviruses are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M) and Nucleocapsid protein (N) (1). The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 (2). In SARS-CoV-2, as with most coronaviruses, proteolytic cleavage of the S protein into S1 and S2 subunits is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (3-5). The S Protein of the SARS-CoV-2 virus, like the SARS-CoV-1 counterpart, binds a metalloproteinase, Angiotensin-Converting Enzyme 2 (ACE-2), but with much higher affinity and faster binding kinetics through the receptor binding domain (RBD) located in the C-terminal region of S1 subunit (6). It has been demonstrated that the S Protein can invade host cells through the CD147/EMMPRIN receptor and mediate membrane fusion (7, 8). Polyclonal antibodies to the RBD of the SARS-CoV-2 protein have been shown to inhibit interaction with the ACE-2 receptor, confirming RBD as an attractive target for vaccinations or antiviral therapy (9). There is also promising work showing that the RBD may be used to detect presence of neutralizing antibodies present in a patient's bloodstream, consistent with developed immunity after exposure to the SARS-CoV-2 (10). Based on amino acid (aa) sequence homology, the SARS-CoV-2 RBD has 73% identity with SARS-CoV-1 RBD, but only 22% homology with the MERS RBD. Several emerging SARS-CoV-2 genomes have been identified including the Omicron, or B.1.1.529, variant. First identified in November 2021 in South Africa, the Omicron variant quickly became the predominant SARS-CoV-2 variant and is considered a variant of concern (VOC). The Omicron variant contains 32 mutations in the S protein, 3 to 4 times more than in other SARS-CoV-2 variants, that potentially affect viral fitness and transmissibility (11). Of these mutations, 15 are located in the RBD domain and allow the Omicron variant to bind ACE-2 with greater affinity and, potentially, increased transmissibility (11, 12). Several additional mutations throughout the S protein have been shown or are predicted to enhance spike cleavage and could aid transmission (13-15). The study of the Omicron variant's impact on immune escape and reduced neutralization activity to monoclonal antibodies along with an increased risk of reinfection, even among vaccinated individuals, remains ongoing (16). The EG.5.1 variant was evolved from Omicron subvariant XBB.1.9 with an additional F456L substitution within RBD (17).

References:

1. Wu, F. *et al.* (2020) *Nature* **579**:265.
2. Tortorici, M.A. and D. Velesler (2019) *Adv. Virus Res.* **105**:93.
3. Bosch, B.J. *et al.* (2003) *J. Virol.* **77**:8801.
4. Belouzard, S. *et al.* (2009) *Proc. Natl. Acad. Sci.* **106**:5871.
5. Millet, J.K. and G.R. Whittaker (2015) *Virus Res.* **202**:120.
6. Ortega, J.T. *et al.* (2020) *EXCLI J.* **19**:410.
7. Wang, K. *et al.* (2020) *bioRxiv* <https://www.biorxiv.org/content/10.1101/2020.03.14.988345v1>.
8. Isabel, S. *et al.* (2020) *Sci Rep.* **10**, 14031. <https://doi.org/10.1038/s41598-020-70827-z>.
9. Tai, W. *et al.* (2020) *Cell. Mol. Immunol.* **17**:613.
10. Okba, N. M. A. *et al.* (2020). *Emerg. Infect. Dis.* <https://doi.org/10.3201/eid2607.200841>.
11. Shah, M. and Woo, H.G. (2021) *bioRxiv* <https://doi.org/10.1101/2021.12.04.471200>.
12. Lupala, C.S. *et al.* (2021) *bioRxiv* <https://doi.org/10.1101/2021.12.10.472102>.
13. Zhang, L. *et al.* (2020) *Nat Commun.* **11**:6013.
14. Lasek-Nesselquist, E. *et al.* (2021) *medRxiv* <https://doi.org/10.1101/2021.03.10.21253285>.
15. Scheepers, C. *et al.* (2021) *medRxiv* <https://doi.org/10.1101/2021.08.20.21262342>.
16. Callaway, E. and Ledford, H. (2021) *Nature* **600**:197.
17. Wang, Q. *et al.* (2023) *bioRxiv* <https://doi.org/10.1101/2023.08.21.553968>.